Galapagos reaps $46M payday as GSK preps PhII study

Belgium's Galapagos NV says that GlaxoSmithKline ($GSK) is prepping a Phase II study of GSK2586184 (formerly GLPG0778)--its JAK1 inhibitor--for ulcerative colitis. The advance triggers a $46 million milestone payday for Galapagos, which partnered with GSK on the program in early 2012. "Galapagos has discovered multiple JAK inhibition molecules, three of which have reached the clinic," said Onno van de Stolpe, CEO of Galapagos. Release

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.